首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1922471

日本生物製藥市場報告：按原料、產品、疾病、產量和地區分類（2026-2034年）

Japan Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 121 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本生物製藥市場規模達611億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到1,635億美元，2026年至2034年的複合年成長率（CAGR）為11.55%。推動市場成長的主要因素包括：對精準醫療方法的需求不斷成長、對罕見疾病治療的日益重視，以及癌症、類風濕性關節炎、多發性硬化症和慢性發炎性疾病等慢性複雜疾病盛行率的上升。

生物製劑涵蓋範圍廣泛，包括單株抗體、疫苗、基因療法和細胞療法等。它們源自於細胞、蛋白質、基因和組織等生物來源成分。與透過化學方法合成的傳統化學藥物不同，生物製劑採用生物技術手段生產。生物製劑透過與體內特定標靶相互作用發揮治療作用。它們以高度特異性和療效著稱，且副作用通常少於傳統藥物。生物製劑能夠刺激免疫系統並誘導免疫反應，而不會引起疾病，有助於人體抵抗各種病毒和細菌的侵害。它們可以根據患者疾病的特定遺傳或分子特徵進行客製化，從而實現個人化治療。生物製劑能夠促進組織再生和創傷治療，且副作用少於傳統化學藥物。它們透過增強人體對癌細胞的免疫反應來幫助治療某些類型的癌症。它們有助於解決影響弱勢群體的罕見疾病和孤兒病問題。生物製劑可用於治療、預防和控制多種疾病和病症。由於生物製劑能夠有效控制症狀、延緩疾病進展，進而改善患者的生活品質，因此日本對生物製劑的需求不斷成長。

日本生物製藥市場趨勢：

目前，癌症、類風濕性關節炎、多發性硬化症和慢性發炎性疾病等慢性複雜疾病的日益普遍是推動日本市場成長的主要因素之一。此外，生物製藥的廣泛應用降低了住院的頻率和嚴重程度，從而推動了日本國內市場的成長。精準醫療需求的不斷成長也為市場帶來了積極的前景。同時，患者對生物製藥益處（例如副作用減少、住院時間縮短和療效持久）的認知不斷提高，為日本的行業投資者提供了豐厚的成長機會。因此，癌症治療中對免疫療法和單株抗體的需求不斷成長，對市場產生了積極影響。此外，生物生產方法的創新使得生物製藥的生產更具成本效益和效率，進一步促進了市場成長。同時，日本生物製藥相關臨床試驗數量的增加也推動了市場成長。此外，大眾對罕見疾病治療日益成長的興趣也是推動市場成長的因素之一。生物技術和基因組學領域的技術進步正在促進新型生物製藥的發現和開發，進一步支持日本市場的成長。

本報告解答的關鍵問題

日本生物製藥市場迄今的發展趨勢及未來幾年的展望
新冠疫情對日本生物製藥市場產生了哪些影響？
日本生物製藥市場依供應來源分類是怎樣的？
日本生物製藥市場依產品分類的組成是什麼？
日本生物製藥市場依疾病分類的組成是什麼？
根據生產方法，日本生物製藥市場的市場組成是怎樣的？
日本生物製藥市場價值鏈的不同階段有哪些？
日本生物製藥市場的主要促進因素和挑戰是什麼？
日本生物製藥市場的結構是怎麼樣的？主要參與者有哪些？
日本生物製藥市場競爭有多激烈？

Japan biologics market size reached USD 61.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 163.5 Billion by 2034, exhibiting a growth rate (CAGR) of 11.55 % during 2026-2034. The growing demand for precision medicine approaches, increasing focus on treating rare diseases, and rising prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, represent some of the key factors driving the market.

Access the full market insights report Request Sample

Biologics comprise a wide range of pharmaceuticals, including monoclonal antibodies, vaccines, gene therapies, and cell-based therapies. They are derived from living organisms or their components, such as cells, proteins, genes, or tissues. They are produced through biotechnological methods, unlike traditional chemical-based drugs that are synthesized through chemical processes. They interact with specific targets in the body to achieve therapeutic effects. They are known for their high specificity and efficacy, often resulting in fewer side effects compared to conventional drugs. They stimulate the immune system to produce an immune response without causing the disease itself, helping to protect individuals from various viruses and bacteria. They can be tailored to specific genetic or molecular characteristics of disease of patient, enabling personalized treatment approaches. They promote tissue regeneration and wound healing and have fewer side-effects as compared to traditional chemical drugs. They aid in treating certain types of cancer by enhancing the immune response of the body against cancer cells. They assist in addressing rare diseases and orphan diseases that affect a small population. They are used to treat, prevent, or manage various medical conditions and diseases. As they improve the quality of life for patients by effectively managing symptoms and slowing disease progression, the demand for biologics is rising in Japan.

JAPAN BIOLOGICS MARKET TRENDS:

At present, the increasing prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, among individuals represents one of the major factors contributing to the market growth in Japan. Moreover, the rising usage of biologics, as they reduce the frequency and severity of hospitalizations, is strengthening the growth of the market in the country. Apart from this, the escalating demand for precision medicine approaches is offering a positive market outlook. Additionally, the increasing awareness among patients about the benefits of biologics, such as fewer side effects, reduced hospital stays, and long-lasting therapeutic effects, is providing lucrative growth opportunities to industry investors in Japan. In line with this, the growing demand for immunotherapies and monoclonal antibodies for treating cancer is influencing the market positively. In addition, innovations in bioproduction methods benefit in cost-effective and efficient production of biologics, which is bolstering the growth of the market. Besides this, the rising number of clinical trials for biologics in the country is propelling the market growth. Furthermore, the increasing focus on treating rare diseases among the masses is impelling the market growth. The technological advancement in biotechnology and genomics enhances the discovery and development of novel biologics, which is also supporting the market growth in Japan.

JAPAN BIOLOGICS MARKET SEGMENTATION:

Source Insights:

To get detailed segment analysis of this market Request Sample
Microbial
Mammalian
Others
Microbial
Mammalian
Others

Product Insights:

Monoclonal Antibodies
Vaccines
Recombinant Proteins
Antisense, RNAi and Molecular Therapy
Others
Monoclonal Antibodies
Vaccines
Recombinant Proteins
Antisense, RNAi and Molecular Therapy
Others

Disease Insights:

Oncology
Immunological Disorders
Cardiovascular Disorders
Hematological Disorders
Others
Oncology
Immunological Disorders
Cardiovascular Disorders
Hematological Disorders
Others

Manufacturing Insights:

Outsourced
In-House
Outsourced
In-House

Regional Insights:

To get detailed regional analysis of this market Request Sample
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the Japan biologics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan biologics market?
What is the breakup of the Japan biologics market on the basis of source?
What is the breakup of the Japan biologics market on the basis of product?
What is the breakup of the Japan biologics market on the basis of disease?
What is the breakup of the Japan biologics market on the basis of manufacturing?
What are the various stages in the value chain of the Japan biologics market?
What are the key driving factors and challenges in the Japan biologics?
What is the structure of the Japan biologics market and who are the key players?
What is the degree of competition in the Japan biologics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biologics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Biologics Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Biologics Market - Breakup by Source

6.1 Microbial
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Mammalian
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Others
- 6.3.1 Historical and Current Market Trends (2020-2025)
- 6.3.2 Market Forecast (2026-2034)

7 Japan Biologics Market - Breakup by Product

7.1 Monoclonal Antibodies
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Vaccines
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Recombinant Proteins
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Antisense, RNAi and Molecular Therapy
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Others
- 7.5.1 Historical and Current Market Trends (2020-2025)
- 7.5.2 Market Forecast (2026-2034)

8 Japan Biologics Market - Breakup by Disease

8.1 Oncology
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Immunological Disorders
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)
8.3 Cardiovascular Disorders
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Forecast (2026-2034)
8.4 Hematological Disorders
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Forecast (2026-2034)
8.5 Others
- 8.5.1 Historical and Current Market Trends (2020-2025)
- 8.5.2 Market Forecast (2026-2034)

9 Japan Biologics Market - Breakup by Manufacturing

9.1 Outsourced
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Forecast (2026-2034)
9.2 In-House
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Forecast (2026-2034)

10 Japan Biologics Market - Breakup by Region

10.1 Kanto Region
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2020-2025)
- 10.1.3 Market Breakup by Source
- 10.1.4 Market Breakup by Product
- 10.1.5 Market Breakup by Disease
- 10.1.6 Market Breakup by Manufacturing
- 10.1.7 Key Players
- 10.1.8 Market Forecast (2026-2034)
10.2 Kansai/Kinki Region
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2020-2025)
- 10.2.3 Market Breakup by Source
- 10.2.4 Market Breakup by Product
- 10.2.5 Market Breakup by Disease
- 10.2.6 Market Breakup by Manufacturing
- 10.2.7 Key Players
- 10.2.8 Market Forecast (2026-2034)
10.3 Central/ Chubu Region
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2020-2025)
- 10.3.3 Market Breakup by Source
- 10.3.4 Market Breakup by Product
- 10.3.5 Market Breakup by Disease
- 10.3.6 Market Breakup by Manufacturing
- 10.3.7 Key Players
- 10.3.8 Market Forecast (2026-2034)
10.4 Kyushu-Okinawa Region
- 10.4.1 Overview
- 10.4.2 Historical and Current Market Trends (2020-2025)
- 10.4.3 Market Breakup by Source
- 10.4.4 Market Breakup by Product
- 10.4.5 Market Breakup by Disease
- 10.4.6 Market Breakup by Manufacturing
- 10.4.7 Key Players
- 10.4.8 Market Forecast (2026-2034)
10.5 Tohoku Region
- 10.5.1 Overview
- 10.5.2 Historical and Current Market Trends (2020-2025)
- 10.5.3 Market Breakup by Source
- 10.5.4 Market Breakup by Product
- 10.5.5 Market Breakup by Disease
- 10.5.6 Market Breakup by Manufacturing
- 10.5.7 Key Players
- 10.5.8 Market Forecast (2026-2034)
10.6 Chugoku Region
- 10.6.1 Overview
- 10.6.2 Historical and Current Market Trends (2020-2025)
- 10.6.3 Market Breakup by Source
- 10.6.4 Market Breakup by Product
- 10.6.5 Market Breakup by Disease
- 10.6.6 Market Breakup by Manufacturing
- 10.6.7 Key Players
- 10.6.8 Market Forecast (2026-2034)
10.7 Hokkaido Region
- 10.7.1 Overview
- 10.7.2 Historical and Current Market Trends (2020-2025)
- 10.7.3 Market Breakup by Source
- 10.7.4 Market Breakup by Product
- 10.7.5 Market Breakup by Disease
- 10.7.6 Market Breakup by Manufacturing
- 10.7.7 Key Players
- 10.7.8 Market Forecast (2026-2034)
10.8 Shikoku Region
- 10.8.1 Overview
- 10.8.2 Historical and Current Market Trends (2020-2025)
- 10.8.3 Market Breakup by Source
- 10.8.4 Market Breakup by Product
- 10.8.5 Market Breakup by Disease
- 10.8.6 Market Breakup by Manufacturing
- 10.8.7 Key Players
- 10.8.8 Market Forecast (2026-2034)

11 Japan Biologics Market - Competitive Landscape

11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant

12 Profiles of Key Players

12.1 Company A
- 12.1.1 Business Overview
- 12.1.2 Product Portfolio
- 12.1.3 Business Strategies
- 12.1.4 SWOT Analysis
- 12.1.5 Major News and Events
12.2 Company B
- 12.2.1 Business Overview
- 12.2.2 Product Portfolio
- 12.2.3 Business Strategies
- 12.2.4 SWOT Analysis
- 12.2.5 Major News and Events
12.3 Company C
- 12.3.1 Business Overview
- 12.3.2 Product Portfolio
- 12.3.3 Business Strategies
- 12.3.4 SWOT Analysis
- 12.3.5 Major News and Events
12.4 Company D
- 12.4.1 Business Overview
- 12.4.2 Product Portfolio
- 12.4.3 Business Strategies
- 12.4.4 SWOT Analysis
- 12.4.5 Major News and Events
12.5 Company E
- 12.5.1 Business Overview
- 12.5.2 Product Portfolio
- 12.5.3 Business Strategies
- 12.5.4 SWOT Analysis
- 12.5.5 Major News and Events

13 Japan Biologics Market - Industry Analysis

13.1 Drivers, Restraints, and Opportunities
- 13.1.1 Overview
- 13.1.2 Drivers
- 13.1.3 Restraints
- 13.1.4 Opportunities
13.2 Porters Five Forces Analysis
- 13.2.1 Overview
- 13.2.2 Bargaining Power of Buyers
- 13.2.3 Bargaining Power of Suppliers
- 13.2.4 Degree of Competition
- 13.2.5 Threat of New Entrants
- 13.2.6 Threat of Substitutes
13.3 Value Chain Analysis